Delcath Sticks With Melblez Chemosaturation But Dumps CEO On FDA Rebuff

FDA’s “complete response” letter requesting further studies is no surprise after a scathing ODAC assessment in May, but with an interim CEO team in place, the company says it’s ready to work things out with regulators.